Workflow
超募资金
icon
Search documents
维远股份上半年预亏去年净利降 2021上市超募20亿元
Zhong Guo Jing Ji Wang· 2025-07-24 06:21
Core Viewpoint - Viyuan Co., Ltd. (维远股份) has announced a significant decline in expected net profit for the first half of 2025, projecting a loss between 175 million to 165 million yuan, compared to a profit of 35.73 million yuan in the same period last year [1] Financial Performance Summary - In 2024, Viyuan Co., Ltd. reported operating revenue of 9.52 billion yuan, representing a year-on-year increase of 35.06% [3] - The net profit attributable to shareholders decreased by 42.62% to 565.89 million yuan, down from 98.62 million yuan in 2023 [3] - The net profit after deducting non-recurring gains and losses was 453.11 million yuan, a decline of 36.85% compared to 71.75 million yuan in the previous year [3] - The net cash flow from operating activities increased by 49.52% to 918.53 million yuan, compared to 613.86 million yuan in 2023 [3] Initial Public Offering (IPO) Details - Viyuan Co., Ltd. raised a total of 4.065 billion yuan through its IPO, with a net amount of 3.88 billion yuan after deducting issuance costs [4] - The final net fundraising amount exceeded the original plan by 2 billion yuan, and the number of investment projects increased by one [4] - The IPO was conducted on September 15, 2021, with an issuance price of 29.56 yuan per share, and the underwriting was managed by CITIC Securities [4]
诚达药业跌13.12% 2022年上市超募11亿光大证券保荐
Zhong Guo Jing Ji Wang· 2025-07-23 08:44
Group 1 - The stock price of Chengda Pharmaceutical (301201.SZ) fell by 13.12% to 27.62 yuan as of the close on July 23, 2023 [1] - Chengda Pharmaceutical was listed on the Shenzhen Stock Exchange's ChiNext board on January 20, 2022, with an initial public offering (IPO) of 24,174,035 shares at a price of 72.69 yuan per share [1] - The highest stock price recorded on the first day of trading was 188.00 yuan, indicating a significant decline since then, as the stock is currently in a state of "breaking" [1] Group 2 - The total amount raised from the IPO was 1,757.21 million yuan, with a net amount of 1,621.45 million yuan after deducting issuance costs [1] - The actual net fundraising exceeded the original planned amount by 1,108.17 million yuan, which was initially set at 513.28 million yuan for various projects and working capital [1] - The total issuance costs for the IPO were 135.76 million yuan, with underwriting fees amounting to 117.93 million yuan [1] Group 3 - On July 3, 2023, Chengda Pharmaceutical announced its 2022 annual equity distribution plan, which includes a cash dividend of 3.00 yuan for every 10 shares and a capital reserve conversion of 6 additional shares for every 10 shares held [2] - The record date for the equity distribution was set for July 6, 2023, and the ex-dividend date was July 7, 2023 [2]
破发股华新环保股东拟减持 上市超募4亿东兴证券保荐
Zhong Guo Jing Ji Wang· 2025-07-23 06:22
截至公告披露日,上海科惠股权投资中心(有限合伙)持有华新环保24,000,000股,占公司总股本的比例 为7.92%,占剔除公司回购专用账户股份后总股本比例为7.96%。上述股份为公司首次公开发行股票前 已发行的股份。 中国经济网北京7月23日讯华新环保(301265)(301265.SZ)昨日晚间披露《关于持股5%以上股东减持股 份的预披露公告》。 根据公告,股东上海科惠股权投资中心(有限合伙)计划自减持计划公告之日起15个交易日之后3个月内 通过集中竞价交易方式减持公司股份,减持数量合计不超过4,800,000股,占公司总股本的1.58%,占剔 除公司回购专用账户股份后总股本的1.59%。上海科惠股权投资中心(有限合伙)属于基金业协会备案的 符合条件的创投基金,其通过集中竞价交易方式减持股份总数不受比例限制。 今年一季报显示,上海科惠股权投资中心(有限合伙)为公司第四大股东。 华新环保首次公开发行股票募集资金总额为100,596.00万元,募集资金净额为92,537.25万元。华新环保 最终募集资金净额比原计划多41,537.25万元。华新环保于2022年12月12日发布的招股说明书显示,该公 司拟募集资 ...
凯尔达上半年扣非亏损 2021上市超募5亿申万宏源保荐
Zhong Guo Jing Ji Wang· 2025-07-21 07:51
Group 1 - The company Kailda (688255.SH) has disclosed a voluntary announcement regarding its performance forecast for the first half of 2025, expecting a net profit attributable to shareholders of between 1.97 million and 2.56 million yuan, a decrease of 21.54 million to 20.95 million yuan compared to the same period last year, representing a year-on-year decline of 91.62% to 89.11% [1] - The company anticipates a net profit attributable to shareholders after deducting non-recurring gains and losses to be between -3.13 million and -2.54 million yuan, a decrease of 21.86 million to 21.27 million yuan compared to the same period last year, indicating a year-on-year decline of 116.71% to 113.56% [1] Group 2 - Kailda's initial public offering raised a total of 924 million yuan, with a net amount of 835 million yuan, exceeding the original plan by 518 million yuan [2] - The company planned to raise 317 million yuan for projects including the construction of an intelligent welding robot production line and an assembly testing laboratory, as well as to supplement working capital [2] - The total issuance costs for the IPO amounted to 88.51 million yuan, with the underwriting fees for the sponsor, Shenwan Hongyuan Securities, totaling 60.99 million yuan [2]
精智达股东2个月减持套现7306万 2023年上市超募3.9亿
Zhong Guo Jing Ji Wang· 2025-07-17 03:42
Core Viewpoint - The company, Jingzhida (688627.SH), announced the completion of a share reduction plan by its major shareholders, which involved a total reduction of 939,607 shares, representing 1% of the company's total share capital [1][3][5]. Shareholder Reduction Details - The shareholders involved in the reduction are Shenzhen Yuanchuangli Qingyuan Venture Capital Partnership, Changzhou Qingyuan Angel Venture Capital Partnership, Suzhou Xinlin Phase II Venture Capital, and Shanghai Lihua Qingyuan Venture Capital, collectively holding 7,094,655 shares, or 7.55% of the total shares [1][2]. - The reduction was executed through centralized bidding from April 28, 2025, to June 23, 2025, with a total reduction of 939,607 shares at a price range of 71.38 to 83.30 CNY per share, amounting to a total of 73,060,503.64 CNY [3][4]. Current Shareholding Status - After the reduction, the remaining shares held by the shareholders are 6,155,048, which is 6.55% of the total share capital [5]. - The original plan allowed for a maximum reduction of 940,118 shares, indicating that the plan was nearly fully executed with only 511 shares remaining untransacted [5]. Company IPO and Fundraising - Jingzhida was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on July 18, 2023, with an initial public offering of 23,502,939 shares at a price of 46.77 CNY per share, raising a total of 109,923.25 million CNY [5]. - The net proceeds from the offering, after deducting issuance costs, amounted to 98,656.46 million CNY, exceeding the original fundraising target by 38,656.46 million CNY [5]. Underwriter Participation - The underwriter, CITIC Securities, participated in the offering with a follow-on investment of approximately 4% of the total shares issued, amounting to 940,118 shares, with an investment of 43,969,318.86 CNY, subject to a 24-month lock-up period [6].
破发股三元生物股东拟减持 2022年上市即巅峰超募26亿
Zhong Guo Jing Ji Wang· 2025-07-11 03:35
Group 1 - The core point of the news is that Shandong Luxin Qisheng Investment Management Co., Ltd. plans to reduce its holdings in Sanyuan Bio by up to 6 million shares within a specified timeframe, which represents 3% of the total share capital after excluding shares held in the company's repurchase account [1] - The reduction will occur through both centralized bidding and block trading, with a maximum of 2 million shares (1% of total share capital) to be sold via centralized bidding and 4 million shares (2% of total share capital) through block trading [1] Group 2 - Sanyuan Bio was listed on the Shenzhen Stock Exchange's ChiNext board on February 10, 2022, with an initial public offering of 33.721 million shares at a price of 109.30 yuan per share, raising a total of 3.686 billion yuan [2] - The company’s shares reached a peak price of 146.00 yuan on the first day of trading but are currently in a state of decline [2] - The net proceeds from the IPO amounted to 3.547 billion yuan, exceeding the original fundraising target of 900 million yuan by 2.647 billion yuan [2] Group 3 - The total issuance costs for Sanyuan Bio's IPO were 139 million yuan, with underwriting fees accounting for 121 million yuan [3] - In June 2022, the company announced a dividend distribution plan for the 2021 fiscal year, distributing 10 yuan in cash per 10 shares and a bonus of 5 shares for every 10 shares held, increasing the total share capital from 135 million to 202 million shares [3]
仲景食品控股股东套现4124万元 上市即巅峰超募4亿元
Zhong Guo Jing Ji Wang· 2025-07-07 05:11
Core Viewpoint - The announcement details the share reduction by the controlling shareholder of Zhongjing Food, indicating a planned reduction of up to 4,380,000 shares, which is 3% of the total share capital, and highlights the recent shareholding changes and the company's financial background [1][2]. Group 1: Shareholding Changes - The controlling shareholder, Henan Wanshi Holdings Co., Ltd., reduced its shareholding from 38.75% to 37.80%, amounting to a decrease of 1,378,910 shares, which is a reduction of 0.94% [1][2]. - The weighted average price of Zhongjing Food's shares during the reduction period (May 28 to July 3, 2025) was 29.91 yuan, resulting in a total reduction amount of 41.24 million yuan [1]. Group 2: Company Background - Zhongjing Food was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on November 23, 2020, with a total public offering of 25 million shares, accounting for 25% of the total shares post-issue [2]. - The company raised a total of 993.5 million yuan, with a net amount of 912.75 million yuan after deducting issuance costs, exceeding the original fundraising plan by 420.75 million yuan [3]. - The funds raised are intended for various projects, including the production line for seasoning sauces and the construction of seasoning ingredient production lines [3]. Group 3: Financial Information - The issuance costs for Zhongjing Food amounted to 80.75 million yuan, with the underwriting fees to Guojin Securities totaling 67.50 million yuan [4]. - The company announced a stock bonus of 4.6 shares for every 10 shares held, along with a pre-tax dividend of 10 yuan, with the record date set for May 13, 2024 [4].
金凯生科上市超募3亿次年扣非净利降9成 中信建投保荐
Zhong Guo Jing Ji Wang· 2025-07-07 03:16
Group 1 - The core viewpoint of the articles highlights the financial performance of Jinkai Biotechnology, showcasing significant growth in Q1 2025 compared to the previous year, despite a decline in 2024 [1] - In Q1 2025, the company achieved operating revenue of 176 million yuan, a year-on-year increase of 41.83%, and a net profit attributable to shareholders of 47.42 million yuan, up 183.24% [1] - For the year 2024, the company reported operating revenue of 497 million yuan, a decrease of 35.19%, and a net profit attributable to shareholders of 38.61 million yuan, down 77.76% [1] Group 2 - Jinkai Biotechnology raised a total of 1.22 billion yuan from its initial public offering, with a net amount of approximately 1.11 billion yuan after deducting issuance costs, exceeding the original plan by 310 million yuan [2] - The company plans to use the raised funds for pharmaceutical intermediates, high-end pharmaceutical products, and to supplement working capital [2] - The annual equity distribution plan for 2023 includes a cash dividend of 8 yuan for every 10 shares and a capital reserve conversion of 4 additional shares for every 10 shares held [2] Group 3 - The actual controllers of Jinkai Biotechnology are Fumin Wang and Lianping Wu, both of whom hold American nationality [3]
索辰科技跌4.59% 2023年上市超募13亿国泰海通保荐
Zhong Guo Jing Ji Wang· 2025-07-04 09:13
Group 1 - The stock price of Suochen Technology (688507.SH) fell by 4.59% to 69.00 yuan, currently in a state of breaking issue [1] - Suochen Technology was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on April 18, 2023, with an issuance of 10.3334 million shares at a price of 245.56 yuan per share [1] - The total amount raised from the initial public offering (IPO) was 253.74697 million yuan, with a net amount of 231.57491 million yuan, exceeding the original plan by 134.68455 million yuan [1] Group 2 - The total issuance costs for the IPO amounted to 22.17206 million yuan (excluding tax), with underwriting fees of 19.23102 million yuan [2] - The company announced a cash dividend of 0.15 yuan per share and a capital reserve increase of 0.48 shares for every share held, resulting in a total distribution of 6.200010 million yuan in cash and an increase of 19.840032 million shares [2] - For the 2023 annual profit distribution, the company plans to distribute a cash dividend of 3.80 yuan for every 10 shares and a capital reserve increase of 4.60 shares for every 10 shares held [2]
华宝新能跌2.54% 2022年上市超募49亿元
Zhong Guo Jing Ji Wang· 2025-07-04 09:13
Core Viewpoint - Huabao New Energy's stock is currently trading at 50.72 yuan, reflecting a decline of 2.54% and is in a state of underperformance since its IPO [1] Group 1: IPO and Fundraising - Huabao New Energy was listed on the Shenzhen Stock Exchange's ChiNext board on September 19, 2022, with an issuance of 24,541,666 shares, accounting for 25.56% of the post-issue total share capital [1] - The IPO price was set at 237.50 yuan per share, and the total funds raised amounted to 582,864.57 million yuan, with a net amount of 559,459.64 million yuan after deducting issuance costs [1] - The net fundraising amount exceeded the original plan by 491,839.64 million yuan, with the funds intended for expansion of portable energy storage products, R&D center construction, brand data center construction, and working capital supplementation [1] Group 2: Dividend Distribution - On May 20, 2023, Huabao New Energy announced its 2022 annual profit distribution plan, which included a cash dividend of 20.83 yuan per 10 shares (totaling 199,968,000.00 yuan) and a capital reserve conversion of 3 shares for every 10 shares held, increasing the total share capital to 124,800,000 shares [2] - The company stated that if there are changes in total share capital between the announcement and the record date, adjustments will be made to the distribution ratio while maintaining the total cash dividend amount [2] Group 3: Future Dividend Plans - On May 24, 2025, Huabao New Energy disclosed its 2024 annual profit distribution plan, proposing a cash dividend of 11.50 yuan per 10 shares, with specific tax treatments for different categories of shareholders [3] - Additionally, the company plans to convert 4 shares for every 10 shares held from its capital reserve [3]